Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) has earned an average rating of “Buy” from the six analysts that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and three have given a strong buy recommendation to the company.
Separately, Chardan Capital raised Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Monday, May 4th.
Check Out Our Latest Stock Report on GLX
Bradmer Pharmaceuticals Stock Performance
Recommended Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- These Stocks Could Win as Wall Street Looks Beyond AI Software
- D.R. Horton Is Defying the Housing Gloom
- Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire
- Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
